The VIVID-1 Study will be evaluating if an investigational drug can reduce the symptoms of Crohn’s disease. The study will consist of approximately 1,100 participants who will initially be divided up into three different groups (one receiving the investigational drug, one receiving an immunosuppressant for comparison, and one receiving placebo for comparison).
Overall, the VIVID-1 Study will last a maximum of 17 months (with participants making around 19 visits to the site) and will be broken up into four periods: